CytoDyn Inc.
CYDY
$0.25
-$0.01-2.00%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.46% | -39.55% | -45.19% | -0.74% | -40.14% |
| Depreciation & Amortization | -- | 44.00% | -28.57% | -50.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.07% | -23.64% | 17.25% | 9.09% | -44.75% |
| Operating Income | -94.07% | 23.64% | -17.25% | -9.09% | 44.75% |
| Income Before Tax | -128.81% | 64.52% | 60.08% | 50.14% | 266.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.81% | 64.52% | 60.08% | 50.14% | 266.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.81% | 64.52% | 60.08% | 50.14% | 266.17% |
| EBIT | -94.07% | 23.64% | -17.25% | -9.09% | 44.75% |
| EBITDA | -94.30% | 23.65% | -17.35% | -9.23% | 44.74% |
| EPS Basic | -128.31% | 69.82% | 66.40% | 59.62% | 228.68% |
| Normalized Basic EPS | -12.00% | 44.44% | 42.22% | 40.48% | 50.98% |
| EPS Diluted | -129.38% | 54.44% | 66.40% | 59.62% | 224.03% |
| Normalized Diluted EPS | -16.67% | 44.44% | 42.22% | 40.48% | 52.94% |
| Average Basic Shares Outstanding | 10.35% | 22.27% | 25.05% | 27.36% | 22.90% |
| Average Diluted Shares Outstanding | 4.53% | 22.27% | 25.05% | 27.36% | 29.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |